Literature DB >> 19506368

Antihypertensive treatment after stroke and all-cause mortality--an analysis of the General Practitioner Research Database (GPRD).

André Michael Toschke1, Charles D A Wolfe, Peter Ulrich Heuschmann, Anthony G Rudd, Martin Gulliford.   

Abstract

BACKGROUND: Randomised controlled trials have shown a beneficial effect of antihypertensive treatment on stroke recurrence. The effect of antihypertensive treatment on survival and recurrence in an unselected sample of the general population, using the General Practice Research Database, was analysed.
METHODS: Cox regression estimating the effect of antihypertensive treatment on survival and stroke recurrence >1 year among 44,244 first-ever strokes in the UK from 1997 to 2006 was adjusted by propensity score analysis considering gender, age, general practice, stroke year, drug prescriptions and diagnostic codes from other diseases.
RESULTS: The EU standardised stroke incidence was 118 per 100,000 (95% CI = 117-120). The 90-day case fatality was 19%. By 90 days after stroke 20,147 (58%) were diagnosed as having hypertension, of whom 75% had received antihypertensive treatment after stroke. After 5 years 68% of the hypertensive stroke patients receiving antihypertensive treatment were alive, while this proportion for patients not prescribed antihypertensive treatment was 59%. This could not be explained by potential confounders with an adjusted relative risk of 0.62 (95% CI = 0.58-0.66; p < 0.001) for antihypertensive treatment and premature death. The adjusted relative risk of antihypertensive treatment on stroke recurrence after 1 year, which was observed in 35% until 5 years after stroke, was 0.92 (95% CI = 0.84-1.01; p = 0.092).
CONCLUSIONS: A high proportion of hypertensive stroke patients did not receive antihypertensive treatment. The protective effect of antihypertensive treatment on survival was higher in this general population than reported in randomised controlled trials, while an effect of antihypertensive treatment on late stroke recurrence was borderline, but not significant. 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19506368     DOI: 10.1159/000223434

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  6 in total

1.  Clinical predictors of death in young and middle-aged patients with ischemic stroke or transient ischemic attack: long-term results of the Vienna Stroke Registry: clinical predictors of ischemic stroke mortality in patients <60 years.

Authors:  Stefan Greisenegger; Sonja Zehetmayer; Julia Ferrari; Wilfried Lang; Johanna Fizek; Eduard Auff; Wolfgang Lalouschek; Wolfgang Serles
Journal:  J Neurol       Date:  2011-02-01       Impact factor: 4.849

2.  Declining 1-year case-fatality of stroke and increasing coverage of vascular risk management: population-based cohort study.

Authors:  Martin C Gulliford; Judith Charlton; Anthony Rudd; Charles D Wolfe; André Michael Toschke
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-02-22       Impact factor: 13.654

3.  Transient ischaemic attack and ischaemic stroke: constructing episodes of care using hospital claims data.

Authors:  Janet K Sluggett; Gillian E Caughey; Michael B Ward; Elizabeth E Roughead; Andrew L Gilbert
Journal:  BMC Res Notes       Date:  2013-04-02

4.  Utility of electronic patient records in primary care for stroke secondary prevention trials.

Authors:  Alex Dregan; Michael A Toschke; Charles D Wolfe; Anthony Rudd; Mark Ashworth; Martin C Gulliford
Journal:  BMC Public Health       Date:  2011-02-07       Impact factor: 3.295

5.  Potential application of item-response theory to interpretation of medical codes in electronic patient records.

Authors:  Alex Dregan; Andy Grieve; Tjeerd van Staa; Martin C Gulliford
Journal:  BMC Med Res Methodol       Date:  2011-12-16       Impact factor: 4.615

6.  UK stroke incidence, mortality and cardiovascular risk management 1999-2008: time-trend analysis from the General Practice Research Database.

Authors:  Sally Lee; Anna C E Shafe; Martin R Cowie
Journal:  BMJ Open       Date:  2011-01-01       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.